See more : Star Cement Limited (STARCEMENT.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Milestone Scientific Inc. (MLSS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Milestone Scientific Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Triton International Limited (TRTN-PB) Income Statement Analysis – Financial Results
- Golden Arrow Resources Corporation (GARWF) Income Statement Analysis – Financial Results
- Myoung Shin Industrial Co.,Ltd (009900.KS) Income Statement Analysis – Financial Results
- Harn Engineering Solutions Public Company Limited (HARN.BK) Income Statement Analysis – Financial Results
- SK hynix Inc. (000660.KS) Income Statement Analysis – Financial Results
Milestone Scientific Inc. (MLSS)
Industry: Medical - Instruments & Supplies
Sector: Healthcare
Website: https://www.milestonescientific.com
About Milestone Scientific Inc.
Milestone Scientific Inc. designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. The company also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, it provides CompuFlo Epidural, a computer controlled anesthesia system for use in various medical applications. Further, the company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Livingston, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.83M | 8.81M | 10.30M | 5.44M | 8.37M | 9.62M | 11.28M | 10.48M | 9.49M | 10.33M | 10.01M | 8.65M | 8.38M | 9.75M | 8.55M | 6.62M | 6.39M | 5.84M | 6.43M | 4.75M | 3.97M | 4.07M | 4.09M | 5.67M | 2.86M | 8.80M | 2.90M | 300.00K |
| Cost of Revenue | 3.03M | 3.91M | 3.99M | 1.82M | 2.66M | 5.19M | 4.31M | 4.18M | 3.05M | 3.63M | 3.20M | 3.06M | 3.02M | 3.53M | 3.46M | 2.68M | 2.90M | 3.04M | 2.52M | 2.42M | 2.00M | 1.98M | 1.97M | 2.91M | 839.46K | 9.60M | 1.60M | 0.00 |
| Gross Profit | 6.79M | 4.90M | 6.31M | 3.62M | 5.72M | 4.43M | 6.97M | 6.31M | 6.44M | 6.70M | 6.81M | 5.59M | 5.36M | 6.22M | 5.09M | 3.94M | 3.49M | 2.81M | 3.91M | 2.34M | 1.97M | 2.09M | 2.12M | 2.77M | 2.02M | -800.00K | 1.30M | 300.00K |
| Gross Profit Ratio | 69.12% | 55.65% | 61.25% | 66.60% | 68.28% | 46.05% | 61.77% | 60.16% | 67.88% | 64.86% | 68.05% | 64.66% | 63.99% | 63.78% | 59.55% | 59.52% | 54.65% | 48.06% | 60.81% | 49.15% | 49.56% | 51.38% | 51.80% | 48.75% | 70.60% | -9.09% | 44.83% | 100.00% |
| Research & Development | 701.38K | 1.15M | 878.21K | 307.85K | 189.92K | 245.64K | 272.75K | 1.27M | 100.86K | 88.24K | 191.35K | 181.98K | 140.05K | 270.49K | 241.32K | 168.52K | 397.35K | 1.01M | 286.26K | 187.99K | 131.02K | 147.71K | 49.94K | 386.25K | 455.33K | 400.00K | 1.00M | 200.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.65M | 11.93M | 11.55M | 9.40M | 7.40M | 5.53M | 5.93M | 6.45M | 6.65M | 6.95M | 5.50M | 6.34M | 5.33M | 6.79M | 5.16M | 3.57M | 3.59M | 5.27M | 8.50M | 7.01M | 9.30M | 7.70M | 2.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 51.41K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.14M | 12.51M | 12.74M | 10.77M | 9.53M | 10.65M | 11.93M | 11.55M | 9.40M | 7.40M | 5.53M | 5.93M | 6.45M | 6.65M | 6.95M | 5.50M | 6.34M | 5.33M | 6.79M | 5.16M | 3.57M | 3.59M | 5.27M | 8.50M | 7.01M | 9.30M | 7.70M | 2.20M |
| Other Expenses | 61.91K | 63.76K | 73.84K | -24.79K | -10.41K | -7.23K | -4.93K | -5.09K | -5.35K | 0.00 | 17.54K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 26.07K | 0.00 | 718.62K | 732.86K | 500.00K | 300.00K | 200.00K |
| Operating Expenses | 13.84M | 13.73M | 13.69M | 11.07M | 9.72M | 10.89M | 12.20M | 12.82M | 9.50M | 7.49M | 5.73M | 6.11M | 6.59M | 6.92M | 7.19M | 5.67M | 6.73M | 6.33M | 7.08M | 5.34M | 3.70M | 3.76M | 5.32M | 9.60M | 8.20M | 10.20M | 9.00M | 2.60M |
| Cost & Expenses | 16.93M | 17.63M | 17.68M | 12.89M | 12.37M | 16.08M | 16.52M | 17.00M | 12.55M | 11.12M | 8.92M | 9.17M | 9.60M | 10.45M | 10.65M | 8.35M | 9.63M | 9.37M | 9.60M | 7.76M | 5.70M | 5.74M | 7.29M | 12.51M | 9.04M | 19.80M | 10.60M | 2.60M |
| Interest Income | 0.00 | 54.61K | 16.36K | 6.71K | 1.54K | 7.45K | 9.30K | 1.29K | 3.84K | 5.06K | 115.00 | 34.00 | 35.00 | 587.00 | 3.15K | 9.02K | 0.00 | 87.41K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 54.61K | 16.36K | 18.08K | 0.00 | 0.00 | 0.00 | 1.29K | 0.00 | 2.67K | 70.80K | 178.97K | 131.84K | 95.14K | 154.03K | 116.37K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 150.36K | 144.38K | 128.93K | 130.28K | 256.47K | 881.29K | 573.15K | 163.37K | 97.38K | 95.84K | 96.12K | 95.13K | 105.39K | 128.64K | 126.39K | 127.24K | 148.91K | 118.76K | 118.15K | 101.92K | 335.22K | 417.99K | 435.18K | 718.62K | 732.86K | 500.00K | 300.00K | 200.00K |
| EBITDA | -6.96M | -8.68M | -7.30M | -7.36M | -3.90M | -5.58M | -4.66M | -6.35M | -2.96M | -694.34K | 1.18M | -596.20K | -1.24M | -572.20K | -2.10M | -1.73M | -3.24M | -3.52M | -3.13M | -2.91M | -1.40M | -1.25M | -2.77M | -6.12M | -5.45M | -10.50M | -7.20M | -2.10M |
| EBITDA Ratio | -70.78% | -98.61% | -70.89% | -135.31% | -1.28% | -41.97% | -41.32% | -60.59% | -31.18% | -15.48% | 2.68% | -6.89% | -11.83% | -7.72% | -22.50% | -33.97% | -53.23% | -63.09% | -62.63% | -61.17% | -35.17% | -32.04% | -69.12% | -103.48% | -162.54% | -123.86% | -262.07% | -766.67% |
| Operating Income | -7.11M | -8.83M | -7.38M | -7.45M | -4.00M | -8.00M | -5.23M | -6.51M | -3.06M | -790.18K | 1.09M | -520.35K | -1.22M | -700.84K | -2.10M | -1.73M | -3.24M | -3.52M | -3.25M | -3.01M | -1.73M | -1.67M | -3.20M | -6.84M | -6.18M | -11.00M | -7.70M | -2.30M |
| Operating Income Ratio | -72.31% | -100.24% | -71.60% | -137.08% | -47.75% | -83.14% | -46.40% | -62.14% | -32.20% | -7.65% | 10.85% | -6.02% | -14.60% | -7.19% | -24.61% | -26.10% | -50.70% | -60.28% | -50.47% | -63.31% | -43.61% | -40.98% | -78.18% | -120.48% | -216.49% | -125.00% | -265.52% | -766.67% |
| Total Other Income/Expenses | 125.53K | 54.61K | 259.82K | -18.08K | -3.64M | 215.00 | 4.37K | -3.80K | -1.51K | -907.81K | 378.23K | -349.95K | -258.50K | 86.33K | 573.43K | 541.13K | 301.55K | 370.52K | 492.87K | 11.34K | 0.00 | 53.93K | 64.49K | -246.28K | -807.60K | 400.00K | 0.00 | 200.00K |
| Income Before Tax | -6.98M | -8.77M | -7.12M | -7.47M | -7.64M | -8.00M | -5.23M | -6.52M | -3.06M | -1.70M | 1.46M | -870.31K | -1.35M | -519.96K | -2.16M | -1.08M | -2.94M | -3.15M | -2.27M | 0.00 | 0.00 | -1.62M | -3.14M | -7.08M | -6.99M | -10.60M | -7.50M | -2.10M |
| Income Before Tax Ratio | -71.04% | -99.62% | -69.08% | -137.41% | -91.27% | -83.13% | -46.36% | -62.18% | -32.22% | -16.43% | 14.63% | -10.06% | -16.12% | -5.33% | -25.23% | -16.31% | -45.98% | -53.94% | -35.26% | 0.00% | 0.00% | -39.66% | -76.60% | -124.82% | -244.77% | -120.45% | -258.62% | -700.00% |
| Income Tax Expense | 0.00 | -66.74K | 333.00 | 15.50K | 18.13K | 23.99K | 19.09K | -19.10K | 36.16K | 9.51K | -843.94K | 7.95K | 258.50K | -86.33K | -573.43K | -541.13K | -301.55K | -370.52K | -413.94K | -11.34K | 680.86K | 770.64K | 791.16K | 673.22K | 790.58K | -300.00K | -300.00K | -400.00K |
| Net Income | -6.93M | -8.71M | -7.12M | -7.49M | -7.66M | -7.43M | -5.19M | -5.95M | -5.47M | -1.70M | 1.46M | -870.31K | -1.48M | -614.51K | -1.53M | -1.19M | -2.94M | -3.15M | -2.75M | -3.00M | -2.41M | -2.44M | -3.99M | -7.51M | -6.97M | -10.70M | -7.40M | -1.90M |
| Net Income Ratio | -70.51% | -98.87% | -69.09% | -137.69% | -91.49% | -77.24% | -45.97% | -56.73% | -57.60% | -16.47% | 14.63% | -10.06% | -17.69% | -6.30% | -17.90% | -17.93% | -45.98% | -53.94% | -42.81% | -63.08% | -60.75% | -59.90% | -97.51% | -132.35% | -244.17% | -121.59% | -255.17% | -633.33% |
| EPS | -0.10 | -0.12 | -0.10 | -0.12 | -0.17 | -0.21 | -0.16 | -0.22 | -0.26 | -0.08 | 0.09 | -0.05 | -0.10 | -0.04 | -0.11 | -0.09 | -0.24 | -0.27 | -0.25 | -0.33 | -0.52 | -0.59 | -1.07 | -2.15 | -2.40 | -3.66 | -3.63 | -1.29 |
| EPS Diluted | -0.10 | -0.12 | -0.10 | -0.12 | -0.17 | -0.21 | -0.16 | -0.22 | -0.26 | -0.08 | 0.08 | -0.05 | -0.10 | -0.04 | -0.11 | -0.09 | -0.24 | -0.27 | -0.25 | -0.33 | -0.52 | -0.59 | -1.07 | -2.15 | -2.40 | -3.66 | -3.63 | -1.29 |
| Weighted Avg Shares Out | 72.78M | 70.61M | 68.83M | 63.06M | 45.74M | 35.30M | 32.70M | 26.97M | 21.03M | 20.06M | 17.13M | 16.08M | 15.17M | 14.82M | 13.39M | 12.67M | 12.14M | 11.79M | 11.01M | 9.15M | 4.67M | 4.16M | 3.71M | 3.50M | 2.91M | 2.92M | 2.04M | 1.47M |
| Weighted Avg Shares Out (Dil) | 72.78M | 70.61M | 68.83M | 63.06M | 45.74M | 35.30M | 32.70M | 26.97M | 21.43M | 20.06M | 17.48M | 16.08M | 15.17M | 14.82M | 13.39M | 12.67M | 12.14M | 11.79M | 11.01M | 9.15M | 4.67M | 4.16M | 3.71M | 3.50M | 2.91M | 2.92M | 2.04M | 1.47M |
Milestone Scientific to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference on December 11th, 2024
ROSELAND, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that its CEO Arjan Haverhals and Chairman Neal Goldman will be...
Milestone Scientific Secures Federal Supply Schedule (FSS) Approval on Contract for CompuFlo® Epidural System
Contract Unlocks Significant Market Opportunities Across Federal Healthcare Systems Contract Unlocks Significant Market Opportunities Across Federal Healthcare Systems
Milestone Scientific Inc. (MLSS) Q3 2024 Earnings Call Transcript
Milestone Scientific Inc. (NYSE:MLSS ) Q3 2024 Earnings Call Transcript November 15, 2024 8:30 AM ET Company Participants David Waldman - Crescendo Communications, Investor Relations Arjan Haverhals - Chief Executive Officer and President Keisha Harcum - Vice President, Finance Conference...
Milestone Scientific Achieves 22% Increase in Revenue for the Third Quarter of 2024
Reports 57% increase in international dental sales for the third quarter of 2024 Advances commercial rollout of CompuFlo® Epidural System across additional pain management clinics following Medicare price assignment in multiple U.S. states ROSELAND, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE)...
Milestone Scientific Announces CEO Transition, with Chairman Neal Goldman Serving as Interim CEO
ROSELAND, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that its Chief Executive Officer Arjan Haverhals will retire from his...
Milestone Scientific Schedules Third Quarter 2024 Financial Results and Business Update Conference Call
ROSELAND, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time...
Milestone Scientific Expands Commercial Rollout of the CompuFlo® Epidural System with Esteemed Pain Management Physician Dr. Elbaz at Hudson Specialty Care
Recent Medicare Price Assignment Driving Increased Access to CompuFlo Milestone Scientific to Attend New York and New Jersey Pain Medicine Congress 2024 ROSELAND, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized...
Milestone Scientific Announces Commercial Rollout of CompuFlo® Epidural System at iHeal Pain Center Following Medicare Price Assignment
Reports Robust Pipeline of Clinics in Trials Across Multiple States through Partnership with Axial Biologics Reports Robust Pipeline of Clinics in Trials Across Multiple States through Partnership with Axial Biologics
Milestone Scientific Inc. (MLSS) Q2 2024 Earnings Call Transcript
Milestone Scientific Inc. (NYSE:MLSS ) Q2 2024 Earnings Conference Call August 15, 2024 8:30 AM ET Company Participants David Waldman - Investor Relations, Crescendo Communications Arjan Haverhals - Chief Executive Officer Keisha Harcum - Vice President, Finance Conference Call Participants...
Milestone Scientific Provides Business Update and Reports Financial Results for the Second Quarter of 2024
Secured Medicare price assignment for the CompuFlo® Epidural System in multiple U.S. states Gross margin for the second quarter of 2024 increased to 76.1% from 65.0% for the same period last year driven by an increase in U.S. e-commerce sales...
Source: https://incomestatements.info
Category: Stock Reports